logo
Plus   Neg
Share
Email

Stock Alert: Lixte Biotechnology Up 55%

Shares of Lixte Biotechnology Holdings Inc. (LIXT) are surging over 55% on Friday morning despite no stock-related news to drive the shares.

LIXT is currently trading at $5.88, up $2.11 or 55.97%, on the Nasdaq.

Lixte Biotechnology operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets.

The company's flagship product is LB-100, which the company believes has serious potential as an anti-cancer agent, whether used alone or in combination with other therapies.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT